ReviewClinical and experimental hepatology2019
Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children.
Review in Clinical and experimental hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Clinical and diagnostic characteristics of non-alcoholic fatty liver disease among Egyptian children and adolescents with type1 diabetes.Diabetology & metabolic syndrome · 2023Article
- Prevalence and associated factors of metabolic-associated fatty liver disease in overweight Finnish children and adolescents.Frontiers in endocrinology · 2023Article
- The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers.Frontiers in nutrition · 2023Article
- Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update.Journal of clinical and translational hepatology · 2022Review
- Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.World journal of clinical pediatrics · 2022Review
- Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammationFrontiers in pharmacology · 2022Article
- The effect of holding a workshop (group and face-to-face training method) on nutrition adjustment on anthropometric indices in children with chronic liver disease.Journal of education and health promotion · 2022Article
- Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.Biomedicines · 2021Review
- ω3PUFAs improve hepatic steatosis in postnatal overfed rats and HepG2 cells by inhibiting acetyl-CoA carboxylase.Food science & nutrition · 2021Article
- Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.International journal of molecular sciences · 2021Review
- Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.International journal of molecular sciences · 2021Review
- Analysis of common causes of liver damage among children 12 years and younger in Weifang.The Journal of international medical research · 2021Article
- From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?Journal of clinical medicine · 2021Review
- Hepatic Steatosis in the Pediatric Population: An Overview of Pathophysiology, Genetics, and Diagnostic Workup.Clinical liver disease · 2021Review
- Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents.Frontiers in pediatrics · 2021Review
- Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.Frontiers in endocrinology · 2021Article
- The effect of nutritional education program on micronutrient intake in children with chronic liver disease: A clinical trial.Journal of education and health promotion · 2021Article
- Diet induces hepatocyte protection in fatty liver disease via modulation of PTEN signaling.Biomedical reports · 2020Article
- Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?Przeglad gastroenterologiczny · 2019Article
- Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.Pediatric health, medicine and therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease. Increasing prevalence of NAFLD in children may be the cause of unfavorable metabolic implications and development of end stage liver disease. NAFLD is a "multiple-hit" disease mediated by several metabolic, environmental, genetic and microbiological mechanisms. Additionally, lipotoxicity, oxidative stress and inflammation predispose to progressive liver damage. According to current guidelines, liver biopsy is an imperfect gold standard for NAFLD diagnosis, but due to its invasive character its use is limited in children and it should be performed only in children who need exclusion of coexisting diseases. Noninvasive methods should be preferred and current research is focused on serum markers and novel imaging or elastographic techniques. Therapeutic approaches for NAFLD are currently focused on lifestyle modification, insulin resistance, dyslipidemia, oxidative stress and the gut microbiome. However, a number of clinical studies on novel therapeutic molecules are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.